Encouragingly, recent advances in medicinal chemistry have discovered an allele-specific KRAS(G12C) covalent inhibitor, sotorasib (AMG-510), that showed clinical benefit for cancer patients and was conditionally approved by the FDA in 20211,7–9. This evidence concerns the gene KRAS and cancer.